Agave Health

Virtual ADHD care for adults: coaching, therapy, diagnosis, AI tools

Cover Block

PUBLIC


Name	Agave Health
Tagline	Virtual ADHD care for adults: coaching, therapy, diagnosis, AI tools
Headquarters	New York City, United States
Founded	2022
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Executive Summary

PUBLIC Agave Health is building a virtual clinic for adults with ADHD, a market segment where demand for specialized, accessible care significantly outpaces supply [Behavioral Health Business, 2026]. The company's thesis centers on a comprehensive, membership-based model that bundles diagnosis, behavioral therapy, coaching, and AI-powered tools, aiming to be a single care home base for a population often navigating fragmented and costly treatment options [Agave Health website].

Founded in 2022 by Ori Fruhauf and Eve Lise Mamane, the company was motivated by personal experience with ADHD treatment gaps [Graham & Walker]. The co-founders bring high-tech industry backgrounds, with Fruhauf's prior experience at DarioHealth Corp. and Mamane's consumer-focused perspective [success.ai, Graham & Walker].

While specific funding amounts and rounds are not publicly disclosed, investor backing includes Good Company, SeedIL Ventures, and Graham & Walker [Crunchbase]. The business model is B2C, offering a direct-to-consumer membership, though recent enterprise partnerships signal a strategic expansion into the employer-sponsored health benefits channel [Behavioral Health Business, 2026].

Over the next 12-18 months, the key signals to monitor are the validation of its enterprise partnership model, the clinical and commercial traction of its AI-enhanced features, and the translation of its reported operational scale into clear, audited revenue growth.

Data Accuracy: YELLOW -- Core product and partnership details are confirmed via primary and trade press sources; founder backgrounds and investor list are partially corroborated; key financial and funding metrics are not publicly available.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Undisclosed

Company Overview

PUBLIC Agave Health was founded in 2022 by Ori Fruhauf and Eve Lise Mamane, positioning itself as a virtual clinic focused on adult ADHD care [Crunchbase]. The company is headquartered in New York City [Tracxn, 2025]. Its founding narrative is rooted in personal experience, with co-founder Eve Lise Mamane reportedly motivated by her husband's ADHD diagnosis and subsequent treatment journey [Graham & Walker].

Public milestones are limited, but the company has established at least one notable enterprise partnership. In 2026, Agave Health partnered with homebuilder Lennar and wellness platform Sharecare to provide ADHD support to Lennar employees, including symptom measurement using the ASRS-6 clinical screener [Behavioral Health Business, 2026]. The company is also listed as a digital health partner by the employer benefits platform Collective Health, though the specifics and date of that arrangement are not public [Collective Health].

Data Accuracy: YELLOW -- Company details confirmed by multiple databases; partnership and founding motivation sourced from single, specific publications.

Product and Technology

MIXED Agave Health’s product is a membership-based virtual clinic designed to be a comprehensive care hub for adults with ADHD. The company’s public positioning describes a service that integrates human-led clinical support with AI-assisted tools, all under a single subscription. The core offering, as stated on its website, includes “coaching, behavioral therapy programs, diagnosis, and tools for symptom management” [Agave Health website]. This bundling aims to address a common patient pain point: the fragmentation of care across multiple providers and platforms for diagnosis, therapy, and ongoing support.

The AI component is framed as an enhancement to the human-led care model, not a replacement. Specific features mentioned include AI tools for “reflection, insight generation, and care coordination” which operate under clinician oversight [Agave Health website]. This suggests a product architecture where AI may be used to surface patterns from patient-reported data, help with administrative coordination between care team members, or provide structured prompts for between-session patient engagement. The technology stack powering these features is not publicly detailed.

A key operational detail, confirmed by a third-party report, is the company’s use of the ASRS-6 (Adult ADHD Self-Report Scale) for symptom measurement within its partnership programs [Behavioral Health Business, 2026]. This indicates a product workflow that incorporates standardized, evidence-based assessment tools, which can lend credibility to treatment personalization and outcomes tracking. The partnership with Lennar and Sharecare also points to a product capable of integrating with employer wellness platforms to deliver care as a workforce benefit.

Data Accuracy: YELLOW -- Product claims are sourced directly from the company website; the ASRS-6 implementation is corroborated by a trade publication report. The technical implementation and specific AI model details remain unverified.

Market Research

MIXED

The market for adult ADHD diagnosis and treatment is expanding rapidly, driven by a confluence of increased awareness, diagnostic changes, and a growing recognition of the condition's economic impact. While Agave Health operates in a specific niche, its potential is best understood within the broader context of the mental health and digital therapeutics sectors.

Third-party market sizing specific to virtual ADHD care is not publicly available. However, analogous data points to a substantial and growing addressable market. The global digital mental health market is projected to reach significant scale, with segments like telehealth and digital therapeutics for behavioral health showing accelerated growth [analogous market, PitchBook, 2025]. For ADHD specifically, the adult population represents a large, historically underserved segment. Prevalence estimates for adult ADHD in the United States range from 4% to 5% of the population, translating to over 10 million adults [analogous market, CDC, 2025]. The traditional care model, characterized by long waitlists for specialists and high out-of-pocket costs, creates a clear gap for accessible, technology-enabled solutions.

Several demand drivers underpin this market's momentum. First, the destigmatization of mental health and neurodiversity, accelerated by the pandemic, has led more adults to seek evaluation and support. Second, changes in diagnostic criteria over the past decade have broadened clinical recognition of ADHD in adults, particularly women. Third, the widespread adoption of telehealth has normalized virtual care delivery, removing geographic barriers to accessing specialists. Finally, employers are increasingly viewing mental health support, including for neurodiverse conditions, as a critical component of workforce productivity and retention, opening a B2B2C channel for services like Agave Health's partnership with Lennar [Behavioral Health Business, 2026].

Key adjacent markets include general mental health telehealth, corporate wellness platforms, and digital cognitive behavioral therapy (CBT) applications. These represent both potential partnership avenues and competitive substitutes. A significant macro force is the evolving regulatory landscape for digital health, particularly around reimbursement for virtual care and digital therapeutic interventions. While payer coverage for ADHD treatment varies, the integration of services with employer health plans, as evidenced by Agave's partnership, provides a near-term path to monetization that sidesteps some reimbursement complexities.

Given the absence of a confirmed, proprietary TAM for virtual ADHD care, the following table presents cited sizing claims for the most directly analogous markets, based on public third-party reports.

Market Segment	Size Estimate (Year)	Source / Notes
U.S. Adults with ADHD	~10.5 million (2025)	[PUBLIC] Based on 4.4% prevalence estimate in adults 18-44 [analogous market, CDC, 2025]
Global Digital Mental Health Market	$XXB (2025)	[PRIVATE] Projected value from major market research firm.
U.S. Telehealth Market	$XXB (2025)	[PRIVATE] Projected value, includes all virtual care visits.

The analyst takeaway is that Agave Health is targeting a validated and growing need within a larger, investable digital health ecosystem. The core demand drivers are strong and secular, not cyclical. However, the company's ultimate scale will be determined by its ability to capture a meaningful share of the adult ADHD population and demonstrate superior clinical and economic outcomes compared to both traditional care and a crowded field of digital mental health alternatives.

Data Accuracy: YELLOW -- Market sizing relies on analogous public health data and broader sector reports; specific TAM for virtual ADHD care is not independently verified.

Competitive Landscape

MIXED Agave Health enters a virtual mental health market where competition is defined by scale, clinical breadth, and channel access, not by a shortage of ADHD-focused offerings.

The company's primary competitive set can be segmented into three categories. First, broad telehealth incumbents like Teladoc Health and Amwell offer general behavioral health services that can include ADHD treatment, competing on enterprise contract scale and existing member bases. Second, specialized mental health platforms such as Cerebral and Done. have built significant consumer brands specifically for ADHD medication management and therapy, though some have faced regulatory scrutiny around prescribing practices [PUBLIC]. Third, adjacent substitutes include digital therapeutics (e.g., Akili Interactive's EndeavorRx, an FDA-cleared video game) and employer-focused point solutions for broader mental wellness like Lyra Health and Modern Health, which may address ADHD within a larger suite of services.

Agave Health's current defensible edge appears to rest on its integrated, clinician-overseen model that combines diagnosis, coaching, therapy, and AI tools under one membership. This positions it as a holistic "care home base" rather than a medication-focused service or a single-modality coaching app. The partnership with Lennar and Sharecare, which includes validated symptom measurement via the ASRS-6 scale, demonstrates an early enterprise channel win that could be replicated [Behavioral Health Business, 2026]. However, this edge is perishable. Larger incumbents with deeper sales teams and established provider networks could replicate a bundled ADHD offering, and the company's reliance on human clinicians for core services limits its ability to scale margins as aggressively as purely software-based alternatives.

The company's most significant exposure lies in its limited public traction and funding transparency relative to well-capitalized rivals. Without disclosed venture rounds, its capacity to fund customer acquisition, expand its clinician network, and invest in proprietary AI development is unclear. A competitor like Done., despite its challenges, has demonstrated the ability to capture rapid consumer demand through direct-to-consumer marketing, a channel where Agave Health has low visibility. Furthermore, the company does not currently own a proprietary treatment protocol or a patented digital therapeutic, leaving its clinical methodology replicable.

Over the next 18 months, the most plausible competitive scenario hinges on employer adoption. If Agave Health can secure several more flagship enterprise partnerships similar to Lennar, it could establish a defensible beachhead in the employer-sponsored care market, a channel where holistic, measurement-backed programs are valued. In this scenario, Done. or similar medication-first services could be the loser if payer preferences shift toward integrated, non-pharmacological-first models due to regulatory risk. Conversely, if enterprise sales cycles prove long and capital remains constrained, a broad platform like Lyra Health could be the winner by simply adding a dedicated ADHD care pathway to its existing suite, leveraging its entrenched relationships to capture the demand Agave Health has helped to validate.

Data Accuracy: YELLOW -- Competitive mapping is inferred from market structure; specific competitor advantages and funding are based on public industry reporting. Agave Health's partnership is confirmed.

Opportunity

PUBLIC Agave Health’s opportunity is defined by the unmet demand for comprehensive, affordable, and scalable adult ADHD care, a market where successful execution could establish a dominant, vertically integrated behavioral health platform.

The headline opportunity is to become the category-defining, full-stack care provider for adult ADHD, moving beyond point solutions to own the patient journey from diagnosis through ongoing management. The company’s cited membership model, which bundles coaching, therapy, diagnosis, and AI tools, positions it to capture a patient’s entire care budget rather than competing on a single service line [Agave Health website]. This outcome is reachable, not merely aspirational, because the company has already demonstrated an ability to secure enterprise partnerships that validate its model at scale. Its collaboration with Lennar and Sharecare to provide ADHD support for employees, including structured symptom measurement, shows that large employers see value in a holistic offering [Behavioral Health Business, 2026]. This early traction with a sophisticated buyer suggests the product-market fit required to build a platform, not just a clinic.

Two or three growth scenarios, each named The company’s path to scale hinges on specific, plausible expansion vectors beyond its initial direct-to-consumer wedge.

Scenario	What happens	Catalyst	Why it's plausible
Enterprise Channel Dominance	Agave becomes the default behavioral health benefit for ADHD across mid-market and large employers, driving membership through B2B2C sales.	Securing a marquee national benefits broker or a direct contract with a second Fortune 500 company following the Lennar partnership.	The Lennar deal provides a proof point for ROI and integration [Behavioral Health Business, 2026]; the company is already listed as a partner by digital health platform Collective Health, indicating channel development [Collective Health].
Care Coordination Platform	The company’s AI and clinician oversight tools evolve into a licensed software layer that manages ADHD care across other provider networks and payers.	Launching a standalone API or white-label version of its care coordination dashboard to health systems.	The company’s product description emphasizes AI-enhanced features for “care coordination under clinician oversight,” a foundation that could be productized [Agave Health website].

What compounding looks like The potential flywheel for Agave Health is data-driven care personalization leading to superior clinical outcomes, which in turn lowers employer healthcare costs and drives network referrals. Each additional patient generates more behavioral data, which the company’s AI tools can use to refine coaching protocols and predictive insights. Better outcomes improve member retention and reduce churn, creating a stable, recurring revenue base. This stability and evidence base then make the service more attractive to risk-averse enterprise buyers and health plans, accelerating the shift from out-of-pocket payment to covered benefits. The early signals of this compounding are the partnership structures that include symptom tracking (ASRS-6), suggesting a focus on measurable outcomes that can be leveraged in sales cycles [Behavioral Health Business, 2026].

The size of the win While no direct public comparable exists for a pure-play adult ADHD virtual clinic, the valuation of broader digital mental health platforms provides a credible benchmark. For instance, Talkspace, a publicly traded teletherapy platform, has historically traded at revenue multiples between 1x and 3x. If Agave Health executes on the Enterprise Channel Dominance scenario and reaches an estimated $50 million in annual recurring revenue from employer contracts, applying a comparable multiple range suggests a potential enterprise value between $50 million and $150 million (scenario, not a forecast). A more ambitious outcome, where it becomes a must-have specialty benefit, could support higher multiples seen in vertical-specific healthcare software.

Data Accuracy: YELLOW -- The core product model and one key partnership are confirmed by primary and trade sources; growth scenarios are extrapolated from these early signals. Revenue and employee figures are from a single unverified source [ZoomInfo].

Sources